Rapid Influenza Diagnostic Testing (RIDT) Market to Witness Rapid Growth by 2026

Posted by aartimurkute on January 14th, 2022

Seasonal influenza, being one of the serious conditions and leading mortality causes worldwide, continues to generate need for rapid critical diagnosis. This will remain the key factor driving the growth of rapid influenza diagnostic testing (RIDT) market. An ongoing study of Fairfield Market Research suggests that the employment of RIDT has been increasing as a form of point-of-care testing (POCT) over the recent past. This is expected to serve as a critical contributor to RIDT market, majorly accounted by the accuracy, and faster outcome of rapid influenza diagnostic testing. With significant growth prospects projected for the diagnostics sector, rapid influenza diagnostic testing is also likely to thrive in the near future. Research expects paediatrics to remain a prime segment for market leaders in RIDT space.

To Read Complete Report of Rapid Influenza Diagnostic Testing (RIDT) Market: https://www.fairfieldmarketresearch.com/report/rapid-influenza-diagnostic-testing-ridt-market

The COVID-19 Push Augured Well for RIDT Providers

High prevalence of influenza A and B that supposedly is responsible for epidemics like bird flu or avian flu further raise the demand for effective, reliable, and specific diagnostic measures against flu variants. The easy usability, faster outcome, high specificity and accuracy, and superior sensitivity gained immense prominence amid the COVID-19 pandemic. Demand from hospitals, and diagnostic centres continues to flow in, favouring the market growth. The rate of flu testing particularly escalated during the initial months of pandemic as a result of a confusion between COVID-19 infection and flu that prevailed among the population.

Opportunities Abound in North America, India to Uplift Prospects of Asia Pacific 

The market for rapid influenza diagnostic testing has been proliferating at the maximum pace in the US as the country continues to lead its way in terms of technology adoption. The entire North American region is likely to provide a strong impetus to market expansion through promoting the research-favourable environment, says the report. Canada will also remain an important growth contributor on the back of its state-of-the-art healthcare infrastructure. The country particularly reflects high growth potential for RIDT owing to an extraordinarily high number of hospitalisations annually. The region continues to be at the forefront of healthcare sophistication, diagnostics, and healthcare trainings in addition to robust support from governments.  

The most important factor that would solidify the top position of North America in rapid influenza diagnostic testing market is the hefty government investments in public education and awareness regarding the diagnosis and treatment of flu. On the other hand, the market participants expect high-value opportunities in Asia Pacific, attributing to the expanding flu patient pool across the region, and large geriatric population at higher risk. Demand for RIDT kits has particularly seen to be mounting in India.

Key Competitors in Global Rapid Influenza Diagnostic Testing Market 

The report would reveal the most significant strategic, and financial insights into some of the key companies driving competition in the global rapid influenza diagnostic testing landscape. Some of the profiled players include Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation (Cepheid), GenMark Diagnostics, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Quidel Corporation, Luminex Corporation, Biocartis, Meridian Bioscience, Inc., Endress+Hauser (Analytik Jena AG), and bioMérieux Inc.